Siemens(US:SIEGY) Di Yi Cai Jing·2025-08-23 07:15Core Viewpoint - The development of multinational medical device companies' R&D models in China has evolved through different stages, with a current focus on open innovation to better meet local market demands [1][4]. Group 1: Company Developments - Siemens Medical Shenzhen Base announced the launch of its open innovation platform, marking a significant milestone with the delivery of its 10,000th medical device [1]. - The Shenzhen base has become Siemens Medical's only global facility with a complete MRI value chain, localizing production from superconducting magnets to integrated systems [1]. - Siemens Medical has invested over 1 billion yuan in a new high-end medical equipment R&D and manufacturing base in Shenzhen, expected to be completed by 2027 [3]. Group 2: R&D Strategy - Siemens Medical has developed several pioneering MRI products in China, including the first 1.5T, 3T, and 7T superconducting MRIs, adapting to local market needs [3]. - The company emphasizes the importance of open innovation, integrating clinical needs into the development of MRI technology to enhance diagnostic capabilities [3]. - The establishment of over 300 core local suppliers over 23 years has contributed to Siemens Medical's R&D innovation in China [3]. Group 3: Industry Trends - The trend of open innovation in the medical device industry is emerging as a response to the increasing competition from local Chinese medical device companies [4]. - The shift from independent R&D to collaborative open innovation reflects the growing opportunities created by local innovations in China [4]. - The competitive landscape in the medical device sector is pushing multinational companies to enhance their R&D efficiency in China [4].